Enabling Latin American population with life-altering conditions to live better lives

by providing early and efficient access to innovative technologies.

 

Therapeutic Areas

OUR ASPIRATION: To become a leading LatAm biotech company delivering innovative treatments to patients with cancers, rare diseases and other specialty conditions

Pint Global

 

 

>> Our subsidiaries 

 

 

Partners

Located in the heart of Europe, Pint Pharma is well situated to service our global partners through our operational teams in Switzerland and Austria. We pride ourselves in providing exceptional expertise and know-how of the Latin American pharmaceutical industry, and strive to provide best-in-class treatment and service to the patient population through strategic alliances with our global business partners..

All Partners
Amicus

Amicus

Eisai

Eisai

Lavipharm

Lavipharm

Onxeo

Onxeo

PumaBiotechnology

PumaBiotechnology

Shire

Shire

ferrer

ferrer

gebro

gebro

News

.

 

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

02 July 2018

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement with Pint Pharma for the commercialization of Beleodaq® (belinostat), Onxeo’s pan-HDAC inhibitor for PTCL (peripheral T-cell lymphoma), in key South American countries.

Read more

Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America

02 July 2018

NEWTOWN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS),

Read more

Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America

02 July 2018

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® (neratinib)

Read more

ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa

02 July 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig® (ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders,

Read more

Pharmacovigilance

If you or a person you know experiences any discomfort or adverse effect that may, or may not, have been caused by treatment with a Pint Pharma product, you can report it to us. Communication with our patients and health professionals who prescribe our medicines is very important to us.

To find the e-mail address for your country, click here.

Pint Pharma has its own pharmacovigilance system that monitors the safety and efficacy of our products when our patients are using them.

Si Ud. o una persona que conoce experimenta alguna molestia o efecto adverso que puede, o no, haber sido causado por el tratamiento con un producto Pint Pharma, puede informarnos lo sucedido. Es muy importante para nosotros la comunicación con nuestros pacientes y profesionales de la salud que prescriben nuestros medicamentos.

Para encontrar la dirección de correo electrónico correspondiente a su país, haga clic aquí.

Pint Pharma cuenta con su propio sistema de farmacovigilancia que monitorea la seguridad y eficacia de nuestros productos cuando nuestros pacientes los están usando.